Literature DB >> 2806473

Sialyltransferase activity in plasma cells of multiple myeloma.

A M Cohen1, D Allalouf, M Djaldetti, K Weigl, N Lehrer, H Levinsky.   

Abstract

A marked elevation of sialyltransferase activity (STA) was observed in a solid tumor of plasma cells, which had been removed from a patient with multiple myeloma (MM), as compared to normal lymphatic tissues. STA was also determined in mononuclear bone marrow cells of 10 patients with MM and found to be 12 times higher than that of bone marrow mononuclear cells from 5 patients with non-malignant disorders (with less than 1% plasma cells in the bone marrow aspirate). A significant correlation was found between STA and the number of plasma cells in the bone marrow aspirate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2806473     DOI: 10.1111/j.1600-0609.1989.tb00281.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Increased sialylation of oligosaccharides on IgG paraproteins--a potential new tumour marker in multiple myeloma.

Authors:  S C Fleming; S Smith; D Knowles; A Skillen; C H Self
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

2.  Glycosylation of IgG B cell receptor (IgG BCR) in multiple myeloma: relationship between sialylation and the signal activity of IgG BCR.

Authors:  Vesna Ilić; Nadezda Milosević-Jovcić; Sonja Petrović; Dragana Marković; Gordana Stefanović; Tatjana Ristić
Journal:  Glycoconj J       Date:  2008-01-11       Impact factor: 2.916

3.  B cells suppress medullary granulopoiesis by an extracellular glycosylation-dependent mechanism.

Authors:  Eric E Irons; Melissa M Lee-Sundlov; Yuqi Zhu; Sriram Neelamegham; Karin M Hoffmeister; Joseph Ty Lau
Journal:  Elife       Date:  2019-08-13       Impact factor: 8.140

4.  Prognostic significance of ST3GAL-1 expression in patients with clear cell renal cell carcinoma.

Authors:  Qi Bai; Li Liu; Yu Xia; Qilai Long; Jiajun Wang; Jiejie Xu; Jianming Guo
Journal:  BMC Cancer       Date:  2015-11-09       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.